Compare ADMA Biologics Inc (ADMA) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs DigitalOcean Holdings Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while DigitalOcean Holdings Inc trades at $121.01 (market cap $15.25B). The key difference: DigitalOcean Holdings Inc is far larger — about 7× ADMA Biologics Inc's market cap, and DigitalOcean Holdings Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | DOCN | |
|---|---|---|
Market Cap | $2.18B | $15.25B |
Sector | Health | Technology |
52-Week High | $20.38 | $181.29 |
52-Week Low | $7.60 | $29.56 |
Enterprise Value | $2.25B | $16.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
DigitalOcean (DOCN) trades at $124.15, up 1.57% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with 29% revenue growth driven by AI demand, and raised full-year guidance. Valuation ratios are elevated, with a P/E of 56.43 and P/S of 13.99, reflecting high growth expectations. Analyst consensus is bullish with a $173.71 price target, though net cash flow turned negative in 2025 due to investing activities.
Outlook is positive given accelerating AI-driven revenue growth and profitability, but risks include high debt levels, competitive cloud market pressures, and stretched valuations. The stock offers upside if execution continues, but investors face volatility from earnings sensitivity and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
